At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Maria-Victoria Mateos provides an update of a randomised, phase III study, which was initiated in 2007, of lenalidomide plus low-dose dexamethasone versus observation in high-risk smouldering multiple myeloma.